|
Lopez-Soley E, Meca-Lallana JE, Llufriu S, Blanco Y, Gomez-Ballesteros R, Maurino J, Perez-Miralles F, Forero L, Calles C, Martinez-Gines ML, Gonzalez-Suarez I, Boyero S, Romero-Pinel L, Sempere AP, Meca-Lallana V, Querol L, Costa-Frossard L, Sepulveda M, Solana E. Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder. J Pers Med. 2022 May 2;12(5):743. doi: 10.3390/jpm12050743. PubMed PMID: 35629165; PubMed Central PMCID: PMC9146457.
AÑO: 2022; IF: 3.4
|
35629165
|
Carreon Guarnizo E, Hernandez Clares R, Castillo Trivino T, Meca Lallana V, Arocas Casan V, Iniesta Martinez F, Olascoaga Urtaza J, Meca Lallana JE. Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders. Neurologia (Engl Ed). 2022 Apr;37(3):178-183. doi: 10.1016/j.nrl.2018.12.013. Epub 2019 Mar 28. English, Spanish. PubMed PMID: 30928236.
AÑO: 2022; IF: 2.283
|
|
Valero-Lopez G, Millan-Pascual J, Iniesta-Martinez F, Delgado-Marin JL, Jimenez-Veiga J, Tejero-Martin AB, Leon-Hernandez A, Zamarro-Parra J, Morales-Ortiz A, Meca-Lallana JE. Treatment with natalizumab during pregnancy in multiple sclerosis: The experience of implementing a clinical practice protocol (NAP-30). Mult Scler Relat Disord. 2022 Oct;66:104038. doi: 10.1016/j.msard.2022.104038. Epub 2022 Jul 7. PubMed PMID: 35870370.
AÑO: 2022; IF: 4.0
|
|
Meca-Lallana JE, Casanova B, Rodriguez-Antiguedad A, Eichau S, Izquierdo G, Duran C, Rio J, Hernandez MA, Calles C, Prieto-Gonzalez JM, Ara JR, Uria DF, Costa-Frossard L, Garcia-Merino A, Oreja-Guevara C. Consensus on early detection of disease progression in patients with multiple sclerosis. Front Neurol. 2022 Jul 28;13:931014. doi: 10.3389/fneur.2022.931014. eCollection 2022. PubMed PMID: 35968319; PubMed Central PMCID: PMC9366521.
AÑO: 2022; IF: 3.4
|
|
Meca-Lallana JE, Fernandez-Prada M, Garcia Vazquez E, Moreno Guillen S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueno S, Fernandez Fernandez O, Izquierdo Ayuso G, Alvarez Cermeno JC, Arnal Garcia C, Arroyo Gonzalez R, Brieva Ruiz L, Calles Hernandez C, Garcia Merino A, Gonzalez Platas M, Hernandez Perez MA, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto Gonzalez JM, Ramio-Torrenta L, Rodriguez-Antiguedad A, Saiz A, Tintore M, Montalban Gairin X. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain. Neurologia (Engl Ed). 2020 Jan 25;37(8):615-630. doi: 10.1016/j.nrl.2019.11.003. Print 2022 Oct. English, Spanish. PubMed PMID: 31987648.
AÑO: 2022; IF: 3.109
|